Toggle Navigation

Latin American Conference on Unwanted Pregnancy and Unsafe Abortion

Gynuity and colleagues participated actively in the Fourth Research Meeting on Unwanted Pregnancy and Unsafe Abortion: Public health Challenges in Latin America and the Caribbean organized by Population Council, Mexico. A presentation on selective use of ultrasound for eligibility assessment for early medical abortion was given by Gynuity staff member during a plenary session on novel contributions to the misoprostol-only regimen, organized by Planned Parenthood Federation of America (PPFA).

Gynuity organized a panel to promote evidence on more liberal programmatic approaches in first trimester mifepristone medical abortion services, which was particularly applicable to programs in the host country of Mexico where a mifepristone product had recently been registered. The panel was entitled “The gold standard in medical abortion: Mifepristone and Misoprostol in the first trimester” and included four presentations:

  • Dr. Ranulfo Ríos Polanco, Director of Legal Pregnancy Termination Services, Hosp. Enrique Cabrera, Mexico City: Experiences providing oral mifepristone and buccal misoprostol in three health facilities in Mexico City
  • Ilana Dzuba, Program Associate, Gynuity: Expanding access to pregnancy termination services with mifepristone after 63 days: Results of a multicenter study.
  • Jennifer Blum, Senior Program Associate, Gynuity: Alternatives to routine follow-up visits at the clinic: the use of a semi-quantitative pregnancy test to identify women who should return for follow-up after medical abortion
  • Mary Fjerstad, Woman Care Global: Provision of safe medical abortion services by non-physician health personnel.

An additional panel was co-organized by Gynuity and PPFA International entitled “Misoprostol for postabortion care (PAC): Experience in Latin America and implications for the health sector”. Gynuity moderated the panel consisting of four presenters from Mexico City, the state of Querétaro, Mexico, Ecuador and Guatemala, who shared their experiences with introduction of a misoprostol for PAC protocol in public and private sector services:

  • Dr. Patricio Sanhueza, Coordinator of Reproductive Health, Mexico City Secretariat of Health. The integration of misoprostol for PAC in Mexico City’s public sector
  • Dr. Lorena Terrazas, Chief of ob/gyn, Hospital de la Mujer y el Niño, Querétaro, Mexico. Applying the norms: The experience of integrating misoprostol for PAC in 3 Mexican states
  • Dr. Jorge Cabrera, Hospital Nacional de Amatitlán, Guatemala. Introduction of a new technology in the absence of national guidelines: The experience of Guatemala
  • Dr. Mónica Cárdenas, Technical Directora, Cemoplaf, Ecuador. Misoprostol for PAC at the primary care level and the cost benefits of the method in private sector services in Ecuador.